Biomarkers of Response to Combination Cabozantinib plus Nivolumab in Advanced Renal Cell Carcinoma

Abstract

Immune checkpoint inhibitors (ICI) have changed the treatment management of metastatic clear cell renal cell carcinoma (mccRCC). However, many patients do not experience durable benefit. Thus, we aim to explore the clinical utility of previously identified biomarkers selecting ICIplusVEGF-TKI therapy vs. VEGF-TKI therapy alone using specimen collection from phase III trial CheckMate 9ER. For markers that we successfully replicate the associative effect, we plan on developing a predictive model for patients treated with ICI+VEGFTKI that can help clinicians estimate the probability that an event will occur. Model replication will be performed using specimens and clinical data from clinical trial JAVELIN Renal 101. In addition, we will also explore the potential associations that were previously uncovered between RNA-based or protein-based biomarkers and resistance to ICI monotherapy that may be overcome when combined with an VEGF-TKI using trials HCRN and OMNIVORE.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2023
Accession Number
AD1212436

Entities

People

  • Sabina Signoretti
  • Toni K Choueiri

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cell Physiological Processes
  • Cells
  • Clinical Trials
  • Combination Therapy
  • Department Of Defense
  • Genes
  • Health Services
  • Kidney Diseases
  • Lymphocytes
  • Medical Personnel
  • Myeloid Cells
  • Neoplasms
  • Predictive Modeling
  • Resistance
  • Therapy

Fields of Study

  • Medicine

Readers

  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.